Rhenman & Partners Asset Management Ab Alkermes Plc. Transaction History

Rhenman & Partners Asset Management Ab

$854 Million
Q3 2025

A detailed history of Rhenman & Partners Asset Management Ab transactions in Alkermes Plc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 94,000 shares of ALKS stock, worth $2.73 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

94,000

Previous 39,000 141.03%

Holding current value

$2.73 Million

Previous $1.12 Million 152.91%

% of portfolio

0.33%

Previous 0.15%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$26.13 - $30.46 $1.44 Million - $1.68 Million	55,000 Added 141.03%	94,000 $2.82 Million
Q1 2025 May 14, 2025	SELL	$28.08 - $36.0 $1.1 Million - $1.4 Million	-38,999 Reduced 50.0%	39,000 $1.29 Million
Q4 2024 Feb 13, 2025	SELL	$25.7 - $31.46 $1.41 Million - $1.73 Million	-55,001 Reduced 41.35%	77,999 $2.24 Million
Q3 2024 Nov 13, 2024	SELL	$23.01 - $28.55 $391,170 - $485,350	-17,000 Reduced 11.33%	133,000 $3.72 Million
Q2 2024 Aug 13, 2024	BUY	$23.21 - $27.24 $928,400 - $1.09 Million	40,000 Added 36.36%	150,000 $3.62 Million

Q1 2024 May 14, 2024	SELL	$26.4 - $32.56 $6.07 Million - $7.49 Million	-230,000 Reduced 67.65%	110,000 $2.98 Million
Q4 2023 Feb 13, 2024	SELL	$23.37 - $28.68 $701,100 - $860,400	-30,000 Reduced 8.11%	340,000 $9.43 Million
Q3 2023 Nov 13, 2023	BUY	$27.17 - $31.97 $1.9 Million - $2.24 Million	70,000 Added 23.33%	370,000 $10.4 Million
Q3 2023 Nov 09, 2023	SELL	$27.17 - $31.97 $1.36 Million - $1.6 Million	-50,000 Reduced 14.29%	300,000 $8.4 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $6.09 Million - $7.23 Million	215,000 Added 159.26%	350,000 $11 Million
Q1 2023 May 11, 2023	SELL	$25.31 - $29.02 $379,650 - $435,300	-15,000 Reduced 10.0%	135,000 $3.81 Million
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $792,000 - $916,200	-30,000 Reduced 16.67%	150,000 $4.47 Million
Q1 2022 May 13, 2022	SELL	$23.07 - $27.99 $692,100 - $839,700	-30,000 Reduced 14.29%	180,000 $4.74 Million
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $2.32 Million - $3.19 Million	-99,354 Reduced 32.12%	210,000 $6.48 Million
Q2 2021 Aug 13, 2021	BUY	$18.78 - $25.15 $1.88 Million - $2.52 Million	100,000 Added 47.77%	309,354 $7.59 Million
Q4 2020 Jan 19, 2021	SELL	$15.39 - $22.1 $1.55 Million - $2.22 Million	-100,646 Reduced 32.47%	209,354 $4.18 Million
Q2 2020 Jul 16, 2020	SELL	$13.31 - $19.41 $1.18 Million - $1.73 Million	-89,000 Reduced 22.31%	310,000 $6.02 Million
Q1 2020 Apr 16, 2020	BUY	$13.06 - $21.24 $378,740 - $615,960	29,000 Added 7.84%	399,000 $5.75 Million
Q4 2019 Jan 17, 2020	BUY	$17.29 - $21.74 $2.59 Million - $3.26 Million	150,000 Added 68.18%	370,000 $7.55 Million
Q3 2019 Oct 16, 2019	BUY	$19.51 - $24.28 $1.94 Million - $2.42 Million	99,601 Added 82.73%	220,000 $4.29 Million
Q1 2019 Apr 11, 2019	SELL	$28.4 - $36.49 $1.53 Million - $1.97 Million	-54,000 Reduced 30.96%	120,399 $4.39 Million
Q4 2018 Feb 05, 2019	SELL	$27.94 - $44.61 $3.55 Million - $5.67 Million	-127,211 Reduced 42.18%	174,399 $5.15 Million
Q3 2018 Oct 03, 2018	BUY	$38.6 - $46.12 $448,146 - $535,453	11,610 Added 4.0%	301,610 $12.8 Million
Q2 2018 Jul 20, 2018	BUY	$40.56 - $51.36 $8.08 Million - $10.2 Million	199,200 Added 219.38%	290,000 $11.9 Million
Q1 2018 Apr 11, 2018	BUY	$53.61 - $67.26 $1.72 Million - $2.15 Million	32,000 Added 54.42%	90,800 $5.26 Million
Q4 2017 Jan 19, 2018	SELL	$47.69 - $55.39 $4.11 Million - $4.77 Million	-86,200 Reduced 59.45%	58,800 $3.22 Million
Q3 2017 Oct 13, 2017	BUY	$49.16 - $54.45 $7.13 Million - $7.9 Million	145,000	145,000 $7.37 Million

Others Institutions Holding ALKS

# of Institutions

402

Shares Held

176M

Call Options Held

901K

Put Options Held

400K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.77B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Alkermes Plc. Transaction History